Results 131 to 140 of about 1,795 (145)

Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors

Haemophilia, 2020
Craig Seaman
exaly  

Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real‐world data

Haemophilia, 2021
Tami Livnat, Ivan Budnik, Assaf Barg
exaly  

Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab

Arteriosclerosis, Thrombosis, and Vascular Biology, 2020
Keiji Nogami, Koji Yada
exaly  

Emicizumab treatment and monitoring in a paediatric cohort: real‐world data

British Journal of Haematology, 2020
Tami Livnat, Ivan Budnik, Assaf Barg
exaly  

Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline

Haemophilia, 2020
P Vincent Jenkins, Anne Riddell, Will Lester   +2 more
exaly  

The societal burden of haemophilia A. III – The potential impact of emicizumab on costs of haemophilia A in Australia

Haemophilia, 2020
Jinjing Li, Laurie Brown, Hai Anh La
exaly  

Emicizumab

2018
Tiede, Andreas, Wörmann, Bernhard, Klamroth, Robert, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss   +4 more
openaire   +1 more source

Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies

Blood Advances, 2019
Veronica Flood, Jordan A Shavit, Steven Pipe   +2 more
exaly  

Real‐world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures

Haemophilia, 2020
Leslie Raffini, Christine Guelcher, Janice Kuhn   +2 more
exaly  

<p>Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A</p>

Drug Design, Development and Therapy, 2020
Sandra Le Quellec
exaly